Nanopore sequencing as a cutting-edge technology for medulloblastoma classification
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noae279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Mathilde Filser und 45 weiteren Autor:innen. Beteiligte Einrichtung: PSL Research University, Paris, France. Hauptthemen laut MEDLINE: Medulloblastoma, Cerebellar Neoplasms, Nanopore Sequencing, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Société Française de lutte contre les Cancers et leucémies de l'Enfant et de l'adolescent, federation Enfants Cancer Santé, NVIDIA.
Abstract (Originalsprache)
Background
Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into 4 molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis. It is critical to establish effective subtyping methods for accurate diagnosis and patient’s management that strikes a delicate balance between improving outcomes and minimizing the risk of comorbidities.
Methods
We evaluated the ability of Nanopore sequencing to provide clinically relevant methylation and copy number profiles of MB. Nanopore sequencing was applied to an EPIC cohort of 44 frozen MB, benchmarked against the gold standard EPIC array, and further evaluated on an integrated diagnosis cohort of 116 MB.
Results
Most MB of both cohorts (42/44; 95.5% and 106/116; 91.4%, respectively) were accurately subgrouped by Nanopore sequencing. Employing Flongle flow cells for 18 MB allowed a more rapid and cost-effective analysis, with 94.4% (17/18) being correctly classified. Nanopore sequencing enabled us to accurately subtype 28/30 (93.3%) MB.
Conclusion
This study, conducted on the largest cohort of MB analyzed with Nanopore sequencing to date, establishes the proof of concept that this modern and innovative technology is well-suited for MB classification. Nanopore sequencing demonstrates a robust capacity for precise subtyping of MB, a critical advancement that holds significant potential for enhancing patient stratification in future clinical trials. Its ability to deliver quick and cost-effective results firmly establishes it as a game-changer in the field of MB classification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PSL Research University, Paris, France.
- Genetics Department, Institut Curie, Paris, France.
- Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Orsay, France.
- Bioinformatics Clinic Unit, Institut Curie, Paris, France.
- Department of Pediatric and Adolescent Oncology, Institut Gustave-Roussy, Villejuif, France.
- INSERM U900, Institut Curie, Paris, France.
ORCID-Profile: Mathilde Filser, Christelle Dufour, David Meyronet, Ludovic Mansuy, Natacha Entz-Werle, Pascale Varlet, Pierre Leblond, Valérie Rigau, François Doz, Olivier Delattre, Franck Bourdeaut, Julien Masliah-Planchon
Förderung
- Société Française de lutte contre les Cancers et leucémies de l'Enfant et de l'adolescent
- federation Enfants Cancer Santé
- NVIDIA
- Robert J. Arceci Innovation Award
- Institut National du Cancer
- Société Française de lutte contre les Cancers et leucémies de l’Enfant et de l’adolescent
Zitieren
APA
Filser, M., Torrejon, J., Merchadou, K., Dufour, C., Girard, E., Bourneix, C., Lemaître, E., Gharsalli, T., Brillet, R., Wong, J., Gentien, D., Rapinat, A., Servant, N., Vasiljevic, A., Bertozzi, A. I., Raimbault, S., Tauziede Espariat, A., Lhermitte, B., Faure-Conter, C., …, & Masliah-Planchon, J. (2025). Nanopore sequencing as a cutting-edge technology for medulloblastoma classification. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae279
Vancouver
Filser M, Torrejon J, Merchadou K, Dufour C, Girard E, Bourneix C, et al. Nanopore sequencing as a cutting-edge technology for medulloblastoma classification. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae279
BibTeX
@article{Filser2025,
author = {Filser, Mathilde and Torrejon, Jacob and Merchadou, Kevin and Dufour, Christelle and Girard, Elodie and Bourneix, Christine and Lemaître, Elisa and Gharsalli, Tarek and Brillet, Riwan and Wong, Jennifer and Gentien, David and Rapinat, Audrey and Servant, Nicolas and Vasiljevic, Alexandre and Bertozzi, Anne Isabelle and Raimbault, Sandra and Tauziede Espariat, Arnault and Lhermitte, Benoit and Faure-Conter, Cécile and Icher, Céline and Berger, Claire and Maurage, Claude Alain and Bodet, Damien and Meyronet, David and Uro-Coste, Emmanuelle and De Carli, Emilie and Forest, Fabien and Palenzuela, Gilles and Chotard, Guillaume and Gauchotte, Guillaume and Sudour, Helene and Mansuy, Ludovic and Deparis, Marianna and Tallegas, Matthias and Faisant, Maxime and Entz-Werle, Natacha and Varlet, Pascale and Leblond, Pierre and Michalak-Provost, Sophie and Proust Houdemont, Stéphanie and Rigau, Valérie and Doz, François and Delattre, Olivier and Bourdeaut, Franck and Ayrault, Olivier and Masliah-Planchon, Julien},
title = {Nanopore sequencing as a cutting-edge technology for medulloblastoma classification},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noae279}
}
EUVIMED